Sep 2026· Expert Review of Neurotherapeutics· Vol 26, pp. 957 - 970· 0 citations· 107 references
Medicine
TL;DR
This review summarizes the diagnostic work-up of children with a first acquired demyelinating syndrome, differential diagnosis, the role of MRI, cerebrospinal fluid (CSF) markers, antibody testing, serum neurofilament light chain, optical pathway assessment and the 2024 McDonald criteria.
Abstract
ABSTRACT Introduction Pediatric-onset multiple sclerosis (POMS) is uncommon but clinically relevant, as inflammatory demyelination occurs during brain maturation. Compared with adult-onset MS, POMS is characterized by higher early relapse rate and MRI inflammatory activity, better recovery from individual relapses, yet disability milestones are reached at a younger age. Early identification is essential to avoid treatment delays, while preventing misdiagnosis of mimics. Areas covered This review summarizes the diagnostic work-up of children with a first acquired demyelinating syndrome, differential diagnosis, the role of MRI, cerebrospinal fluid (CSF) markers, antibody testing, serum neurofilament light chain, optical pathway assessment and the 2024 McDonald criteria. Early prognostic factors and therapeutic implications are discussed, including evidence supporting early high-efficacy therapies in selected children. References for this review were identified through searches of PubMed, authors’ own files, abstracts presented at main congresses, from 1 January 1979 to 1 July 2026. Expert opinion Early identification of POMS requires integrated assessment of clinical presentation, MRI lesion topography, CSF findings, antibody testing, and emerging biomarkers. Although central vein sign, paramagnetic rim lesions, kappa free light chains and serum neurofilament light chain may refine stratification, pediatric validation remains incomplete. Earlier, more accurate diagnosis should support individualized treatment to preserve long-term outcomes.
Key updates include expansion of dissemination in space to incorporate the optic nerve, integration of relapsing and progressive onset MS within a unified diagnostic framework, provision for diagnosis in selected asymptomatic individuals, dispensing with the requirement for dissemination of time in certain situations a...
P. Siriratnam, Mineesh Datta, Katherine A. Buzzard et al.· Autoimmunity Reviews· 0 citations
Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed.
Moein Amin, Kaitlyn N. Palmer, A. Samara et al.· Drugs· 0 citations
Background and Objectives: Spinal cord stroke (SCS) is an underrecognized cause of severe acute myelopathy in children that can be misdiagnosed as an infectious or inflammatory process. Limited characterization of clinical and neuroimaging features of pediatric SCS impede timely and accurate diagnoses. Our objectives w...
D. Acero-Garcés, Eliza Gordon-Lipkin, Doris D. M. Lin et al.· Neurology Clinical Practice· 0 citations
Current evidence suggests that LOBD likely represents a heterogeneous condition with multiple underlying mechanisms, including vascular burden, neurodegenerative processes, and age-related biological vulnerability, including vascular burden, neurodegenerative processes, and age-related biological vulnerability.
Bruno Lancksweerdt, A. Van Duyse, B. Sabbe· Expert Review of Neurotherap...· 0 citations
The Gulf POMS evidence base is real but narrow, concentrated, and heterogeneous; a scoping review is currently the more informative synthesis than a quantitative meta-analysis, which supports a harmonized, multi-country Gulf pediatric MS registry with standardized outcome reporting, including neurocognitive and quality...
E. Shosha, N. Qadi, Rakan S. Alromayan et al.· Biomedicines· 0 citations
Patients with LOMS tend to have a higher prevalence of PPMS, a greater burden of comorbidities, higher baseline disability, lower relapse activity, and a shorter time to CDP.
A. Fouad, Abdallah Saad, Hadeer Mohamed Abd El-Aziz et al.· Multiple Sclerosis and Relat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.